Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
Uncovering germline mutation risk in children with unilateral retinoblastoma
Study focuses on ascertaining the risk of patients developing additional tumors
Less may be more for intravitreal bevacizumab in retinopathy of prematurity
Lower dose performs as effectively as a higher dose when treating ROP.
Suprachoroidal injection successfully delivers drug to the macula, posterior segment
Suprachoroidal injections provide safe, effective drug delivery to target choroidal, retinal tissues.
Decreased retinal vascular density linked to moderate-to-severe COVID-19 pneumonia
Investigators identified that patients with moderate and severe SARS-CoV-2 pneumonia have decreased central retinal vascular density compared with patients who were asymptomatic/paucisymptomatic or control subjects.
Intensive multimodal therapy found to be safe, effective for orbital retinoblastoma
Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.
PDS ushers in a new era in treatment of wet AMD
The implant achieves impressive efficacy and reduces treatment burden.
Intravitreal injections for retinopathy of prematurity prove safe, effective in many cases
Luis Acaba-Berrocal, MD, of the Illinois Eye and Ear Infirmary in Chicago, worked with a group of colleagues to conduct a multicenter, retrospective, consecutive study of infants with ROP who had been treated with intravitreal anti-VEGF injections between 2008 and 2020 in light of the dearth of real-world data on the topic.
Controlling intraocular inflammation associated with brolucizumab
Taiichi Hikichi, MD, counteracted the potential inflammatory effect of brolucizumab by combining its administration with a sub-Tenon’s capsule injection of triamcinolone acetonide.
Reshaping retina treatment with faricimab
The first FDA-approved bispecific antibody for the eye targets two leading causes of vision loss.
From intravitreal injections to gene therapy, new AMD treatments are on the horizon
Reducing the treatment burden is a prime goal for emerging AMD therapies.
Highlighting major advances in retinal diagnostics, therapeutics presented at Angiogenesis 2022
Presenters at the conference provided new evidence about detecting geography atrophy and wet and dry AMD early and predicting disease progression. Investigators are also focused on finding cures for inherited retinal diseases.
COVID-19 linked to retina concerns comparable to Purtscher retinopathy
Investigators at the Eye Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy, found that the appearance of the retina and optic disc was associated with the SARS-CoV-2 virus.
Conquering the crisis of diabetes among Black Americans
Leading the charge for a multifactorial approach to combat diabetes, Kristen Nwanyanwu, MD, MBA, MHS, and her team have embraced the need for a multi-pronged program to address health disparities in diabetic retinopathy.
RNA therapy may halt the progression of Stargardt disease
Investigators in the Netherlands have developed an RNA therapy to halt the progression of Stargardt disease.
Faricimab: Safe, durable treatment for DME over the long term
After 2 years, the improvements in vision and anatomy were sustained with extended dosing out to every 16 weeks in a high percentage of patients.
KALAHARI study finds THR-149 to be safe, well-tolerated as treatment for DME
KALAHARI study finds THR-149 to be safe, well-tolerated with preliminary efficacy as treatment for DME patients who respond suboptimally to anti-VEGF.
PDS maintains visual, anatomic benefits over long term in Portal extension trial
Most patients (95%) with the PDS implanted did not need supplemental treatment before the refills, indicating the persistence and durability of the treatment.
Positive results from DAVIO trial investigating EYP-1901 for wet AMD
Previously treated patients showed significantly reduced treatment burden.
Growth of GA lesions slowed by avacincaptad pegol in clinical trial
In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Glenn J. Jaffe, MD, noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared to sham treatment.
Subretinal implant found to be safe, well-tolerated in patients with advanced dry AMD
This study showed that an investigational subretinal implant, CPCB-RPE1, containing allogeneic human embryonic stem cell-derived RPE cells, was safe and well-tolerated by patients with dry AMD.
Initiation of inflammatory cascade inhibited by once-daily oral dose of Xiflam
A once-daily oral drug targets inflammatory processes and thus far has been found to be well tolerated in a phase 2 safety trial.
FOTO-TIA study: Retinal microvascular changes may not predict future ischemic events
Investigators search for a link between transient ischemic attacks and changes in the retina.
Study results: AGTC-501 gene therapy shows vision gains for X-linked RP
A study finds acceptable outcomes, vision and microperimetry improvements at higher doses.
Program for Angiogenesis 2022 ignites excitement in ophthalmologists
The meeting places a special emphasis on pharmacotherapies in the pipeline for the treatment of neovascular exudative diseases of the eye and how they will affect clinical practice and Medicare.
Novel deep learning tool shows promise in classifying DME
Approach shows potential as a promising second-line screening tool for patients with diabetes.
Managing DME and increasing vision effectively with intravitreal triamcinolone
The improvement became evident during an average time of 6 months.
Pupillary sizes differ in active and resolved COVID-19 cases, study finds
The investigators believe that, based on their findings, the impact of COVID-19 on the autonomous nervous system warrants further prospective studies and assessment of pupillary function might be a useful test for determining autonomic dysfunction.
Inserting intravitreal dexamethasone implants in vitrectomized vs non-vitrectomized eyes
Consecutive intravitreal dexamethasone treatments may be beneficial for patients with DME patients who had undergone a previous vitrectomy.
Diagnosing Parkinson’s disease aided by OCT/OCTA ocular biomarkers
Imaging study revealed specific retinal and choroidal changes associated with the disease.
Meeting the need of persistent long COVID-19 symptoms
Investigators have cited the need for pharmacologic and non-pharmacologic interventions to improve the ongoing burden after hospitalization for COVID-19.
2 Clarke Drive Cranbury, NJ 08512